Evaluation of RAR-B2 and ZMYND -8 promoter methylation in tumor and tumor tissue and free margin in patients with lung cancer

Abstract

Lung cancer stays as one of the most lethal carcinomas world widely because of its late diagnosis. One of the DNA modifications is methylation, which is as one of the primary alterations of tumor development, consisting fascinating indicators for cancer diagnosis. In this study, we investigated ZMYND-8 and RAR-B2 genes methylation in NSCLC as would be new epigenetic tool. Methods: to begin with, so as to find out potential diagnostic capability of ZMYND-8 and RAR-B2 genes methylation we entirely surfed DNA methylation microarrays from the Cancer Genome Atlas (TCGA) data of NSCLC samples. Additionally, we took advantage of using q-MSP, in a number of samples comprising NSCLC tumors and neighboring normal tissues, ZMYND-8 and RAR-B2 genes methylation grades were acquired. Results: Our finding displayed major hypo methylation of ZMYND-8 and hypermethylation of RAR-B2 in NSCLC samples compared to neighboring normal specimens which showed significant correlation with the clinical stage of malignancy. In addition, the great precision of, ZMYND-8 and RAR-B2 methylations as a dependable cancer diagnosis indicator in NSCLC was confirmed drawing the ROC curve analysis with an AUC value of 0.751 and of 0.8676 respectively for ZMYND-8 and RAR-B2. Additional study of other dominant cancer entities in TCGA displayed that RAR-B2 higher methylation degree and ZMYND-8 lower methylation degree are a prevalent change in tumor evolution which possibly will be considered as a probable diagnostic biomarker for lung cancer.